Det nye forumet finner du her

Tilbake til: Farma og medisin
Innlegg av: Snøffelen (22.01.18 23:05 ), lest 2762 ganger
Ticker: PCIB
Endret: 22.01.18 23:07

RE^1: PCIB - hvor langt ned er dere villige til å selge ? (50 ?)

BMS har kjøpt tilbake Varlatinib fra Alsan

https://www.fiercebiotech.com/biotech/bms-buys-back-early-oncology-rights-from-asia-partner

BMS buys back early oncology rights from Asia partner
by Stacy Lawrence | Aug 10, 2016 11:39am

"Aslan’s two most advanced candidates are in Phase II testing: varlitinib, a pan-HER inhibitor in development in cholangiocarcinoma, gastric and breast cancers that’s in-licensed from Array Biopharma ($ARRY), and ASLAN002, a RON and MET inhibitor being developed for gastric and breast cancers."

Husker ikke alle kliniske detaljer på Varlatinib men kan få postet det ved anledning.
Men det var ikke i nærheten en gang, as I recall.